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Background: Hypochloremia is a strong negative prognostic factor in humans with
congestive heart failure (CHF), but the implications of electrolyte abnormalities in
small animals with acute CHF are unclear.
Objectives: To document electrolyte abnormalities present upon admission of small
animals with acute CHF, and to assess the relationship between electrolyte concen-
trations and diuretic dose, duration of hospitalization and survival time.
Animals: Forty-six dogs and 34 cats with first onset of acute CHF.
Methods: Retrospective study. The associations between electrolyte concentrations
and diuretic doses were evaluated with Spearman rank correlation coefficients. Rela-
tionship with duration of hospitalization and survival were assessed by simple linear
regression and Cox proportional hazard regression, respectively.
Results: The most commonly encountered electrolyte anomaly was hypochloremia
observed in 24% (9/46 dogs and 10/34 cats) of cases. In dogs only, a significant neg-
ative correlation was identified between serum chloride concentrations at admission
(median 113 mmol/L [97-125]) and furosemide doses both at discharge (median
5.2 mg/kg/day [1.72-9.57]; r = 0.59; P < .001) and at end-stage heart failure
(median 4.7 mg/kg/day [2.02-7.28]; r = 0.62; P = .005). No significant hazard ratios
were found for duration of hospitalization nor survival time for any of the electrolyte
concentrations.
Conclusions and Clinical Importance: The observed association between serum chlo-
ride concentrations and diuretic doses suggests that hypochloremia could serve as a
marker of disease severity and therapeutic response in dogs with acute CHF.
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1 | INTRODUCTION
In both human and veterinary medicine, electrolyte abnormalities
occur in congestive heart failure (CHF) cases. This is thought to be
Abbreviations: AVS, arginine vasopressin system; CHF, congestive heart failure; Cl, chloride;
K, potassium; Na, sodium; RAAS, renin-angiotensin-aldosterone system.
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due to neurohormonal activation by the renin-angiotensin-
aldosterone (RAAS) and arginine vasopressin (AVS) systems, and
because of the diuretic therapy initiated in such cases.1 For decades,
the fundamental role of sodium (Na) in fluid homeostasis and heart
failure (HF) progression has been well established in human medi-
cine.2 Hyponatremia has sparked extensive interest as a strong predic-
tor of adverse events, including worsened survival, rehospitalization
and prolonged length of hospitalization in people with CHF.3-5 A ret-
rospective study performed in dogs with acute CHF demonstrated
similar results, with significantly lower Na concentrations in non-
survivors.6 However, recent evidence suggests that serum chloride
(Cl) concentrations, either at admission or at discharge, are more
closely related to survival, renal function, and loop diuretic doses than
Na in people with both acute or chronic HF.7-10 The reason for this is
suspected to be multifactorial, and related to Cl's unique neurohor-
monal and homeostatic roles.11 While the fluid retention caused by
maladaptive neurohormonal activation and arginine vasopressin
release creates a “dilutional effect” decreasing both Na and Cl in
equivalent proportions,1 the formal perception of Cl operating only as
a passive anion linked to Na concentrations is currently contested. It
is now thought that Cl has a specific and critical role in regulating HF
physiology in people.12 Human patients with low serum Cl concentra-
tions are suspected of having an excessive RAAS activation and
potentially decreased diuretic efficacy, also commonly referred to as
diuretic resistance.8,12-14 In dogs with chronic CHF, serum Cl concen-
tration is a strong differentiator between heart disease stages.15 A
cut-off of <103.5 mmol/L accurately identifies stage D cases, which
comprises dogs suspected of having or developing diuretic resistance.
This unveils a potential connection between hypochloremia and
diuretic resistance in dogs with chronic CHF.15 However, data on the
implications of electrolyte abnormalities on diuretic dosing, diuretic
response and prognostic variables in small animals with acute presen-
tation of CHF are lacking. Thus, the aims of this retrospective study in
dogs and cats with acute CHF were 3-fold: (a) to document the elec-
trolyte abnormalities present upon admission, (b) to assess the associ-
ation between serum electrolyte concentrations and diuretic dose,
and (c) to evaluate the prognostic impact of serum electrolyte concen-
trations, as reflected by duration of hospitalization and survival time.
2 | MATERIAL AND METHODS
2.1 | Case selection
The medical records database of the Small Animal Clinic, Faculty of
Veterinary Medicine of Ghent University were retrospectively
reviewed for all dogs and cats presented with clinical signs of acute
CHF, between January 2012 and August 2019. Only the first episode
of acute CHF of each animal was recorded, and animals with a history
of previous CHF episodes were excluded. The previous administration
of any cardiac medication was not an exclusion criterion, as long as
the animal was presented with its first clinically-overt episode of
acute CHF requiring hospitalization.
Cases were eligible for inclusion if the diagnosis of acute CHF
was confirmed by medical imaging, and if a full serum electrolyte
panel was available at the time of admission. The diagnosis was con-
firmed by a board-certified cardiologist, a supervised cardiology resi-
dent or by experienced cardiology staff clinicians. Depending on the
clinical stability of the animal at presentation, the diagnosis was con-
firmed by 1 of the following: (a) thoracic radiographs and complete
echocardiographic examination or (b) point-of-care lung ultrasonogra-
phy associated with emergency echocardiography for confirmation of
left atrial enlargement with pulmonary edema, pleural effusion, or
both for left-sided CHF cases, or right atrial enlargement and ascites,
pleural effusion, or both for right-sided CHF cases.
In dogs and cats deemed clinically stable after initial stabilization,
complete echocardiographic examinations were conducted, with
transthoracic 2D, M-mode, and conventional Doppler echocardiogra-
phy, using a dedicated ultrasound unit (Vivid 7 or Vivid E95, General
Electric Medical Systems, USA). Animals were placed in right and left
lateral recumbency, and simultaneously, a 1-lead electrocardiogram
was recorded. Standard right parasternal (long and short axis) and left
apical parasternal views were used for data acquisition. In cases
remaining clinically unstable, exhibiting signs of respiratory distress
incompatible with prolonged examinations, emergency echocardiogra-
phy was limited to right parasternal long and short axis views. To con-
firm the diagnosis of CHF in unstable animals, point-of care lung
ultrasonography, abdominal ultrasonography, or both of the modali-
ties were performed with a mobile ultrasound unit equipped with a
microconvex transducer dedicated to emergency and intensive care
(MyLab30CV, Esaote, Italy), as previously described.16,17
Exclusion criteria were concurrent neoplasia, significant systemic
disease (defined as any type of uncontrolled systemic disorder
suspected to affect the animal's lifespan), interventional or surgical
management, or the presence of missing data from the records. Cases
suspected of having important renal impairment, defined by a creati-
nine value above 251 μmol/L, were excluded from the study. Given
the potential of diuretic therapy to induce prerenal azotemia, evi-
dence of increased creatinine between 125-250 μmol/L in dogs and
140-250 μmol/L in cats that already received diuretic therapy prior to
admission was not considered an exclusion criterion. Cases suspected
of reversible cardiomyopathy based on follow-up examinations (eg,
high suspicion of transient myocardial thickening in cats with evidence
of improvement of the echocardiographic anomalies), or cases who
died from noncardiac or mixed reasons were excluded from the sur-
vival analysis.
2.2 | Data collection
Medical records were reviewed and the following data was tabulated
in a digital spreadsheet (Microsoft Excel 16.30): signalment, clinical
signs, ongoing medications, admission serum electrolyte concentra-
tions including Na, potassium (K) and Cl, duration of hospitalization
(defined as the number of hours spent by the patient in the clinic),
doses of drugs prescribed at discharge (in mg/kg/day), loop diuretic
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doses at end-stage disease (defined as the last diuretic dose available
before death, in mg/kg/day), and date of death or date when the ani-
mal was lost to follow-up. Primary care veterinarians and owners were
contacted when follow up data was lacking from the records.
Serum electrolyte concentrations were measured by the use of an
auto-analyzer (Catalyst Dx Chemistry Analyzer, IDEXX). The respec-
tive reference intervals, as defined by IDEXX company, were
144-160 mmol/L for Na, 3.5-5.8 mmol/L for K and 109-122 mmol/L
for Cl in dogs, and 150-165 mmol/L for Na, 3.5-5.8 mmol/L for K and
112-129 mmol/L for Cl in cats. Depending on the serum concentra-
tion of each electrolyte, cases were assigned a category using the
lower and upper reference limits, defined as “hypo-,” “normo-,”or
“hyper-.”
2.3 | Statistical analysis
All statistical analyses were conducted in R version 3.5.2 (“Eggshel
Igloo”). General significance level was set at α ≤ 0.05. A Bonferroni
correction was applied whenever a correction for multiple testing was
necessary and the adapted significance threshold is mentioned
between brackets. All analyses were ran in parallel for the 2 species.
For the descriptive analysis, it was decided to report every variable as
median and range as some variables were normally distributed in
1 species but not in the other. Electrolyte abnormalities observed
upon admission were described in both the general sample, in the sub-
group of dogs and cats who did not receive any loop diuretic prior to
admission (defined as “furosemide-naïve” dogs and cats respectively),
and in left- and right-sided CHF subgroups.
In the subset of dogs (n = 43) and cats (n = 32) that survived the
hospitalization period, the association between electrolyte concentra-
tions, loop-diuretic doses and hospitalization duration were assessed.
On account of the low number of animals included, cases receiving a
loop-diuretic other than furosemide (5 dogs and 2 cats) were excluded
from the analyses focusing on diuretic doses. The correlations
between Na, K, Cl and corrected Cl concentrations (calculated as pre-
viously described18) on admission and the furosemide total dose at
discharge and end-stage, were calculated using Spearman rank corre-
lation coefficients (α ≤ 0.05/4, n = 43 dogs and n = 32 cats at dis-
charge, n = 27 dogs and n = 14 cats at end-stage). Depending on the
correlation coefficient (r) observed, the correlation was described as
mild (0.30 < r < 0.50), moderate (0.50 < r < 0.70), or strong (>0.70).19
Next, a Wilcoxon rank sum test was used to evaluate whether receiv-
ing furosemide before hospitalization influenced Cl concentrations on
admission (α ≤ 0.05/4). Correlation analysis was repeated in the sub-
set of dogs (n = 26 at discharge and n = 16 at end-stage) and cats
(n = 20 at discharge and n = 8 at end-stage) that did not receive furo-
semide prior to admission (α ≤ 0.05/4) (defined as “furosemide-naïve”
animals). Finally, a simple linear regression model with electrolyte con-
centrations as independent variables and duration of hospitalization
as dependent variable was made to evaluate the significance of the
individual independent variables (α ≤ 0.05/4).
A survival analysis was conducted in all cats and dogs except
those that died due to noncardiac reasons and cases suspected of
reversible cardiomyopathies (n = 42 dogs and n = 30 cats), and cen-
soring animals that were still alive at the end of the study period
(6 dogs and 7 cats). Using a Cox proportional hazards regression
model, the potential effect of electrolyte concentrations on time to
cardiac mortality was assessed.
Since left- and right-sided CHF have a different pathophysiology,
treatment regimen and prognosis, the analyses mentioned above were
also done in the subset of animals in left-sided CHF (n = 41 dogs and
31 cats; α ≤ 0.05/4).
3 | RESULTS
3.1 | Study sample
In the predefined time span between January 2012 and August 2019,
434 medical records of small animals presented for acute CHF were
reviewed. Three hundred and fifty-four records were excluded with
regards to the criteria listed above, and thus 80 cases (46 dogs and
34 cats) met the inclusion criteria. The median age of the dogs was
TABLE 1 Clinical data of the dogs included in the retrospective





Tricuspid dysplasia 3 7%
Mitral dysplasia 2 4%
Aortic stenosis 2 4%
Arrhythmias





Exercise intolerance 17 37%
Lethargy 12 26%




Pulmonary edema 41 89%
Pleural effusion 14 30%
Ascites 10 22%
Abbreviations: DCM, dilated cardiomyopathy; MMVD, myxomatous mitral
valve disease; SVT, supraventricular tachycardia.
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9.5 years (range, 1-16 years) and the median weight was 12 kg (range,
2.35-80 kg). The study sample consisted of 28 males and 18 females.
The most common breed was Cavalier King Charles Spaniels (n = 7),
followed by Chihuahuas, crossed breeds (n = 4 each) and German
Shepherds (n = 3). The clinical data of the included dogs is presented
in Table 1. Most dogs presented with at least 2 clinical signs (42/46,
91%), with the most common combination being tachypnea, dyspnea
or both, and coughing (22/46, 48%). Forty-one dogs were in left-sided
CHF and 5 dogs were in right-sided CHF. The treatments received
prior to admission are detailed in Table 2. Thirty-three dogs were
already on treatment at the time of admission. Sixteen dogs (35%) had
already received furosemide at the time of admission. Four dogs
received an injection of furosemide by the primary care veterinarian
at the time of referral (exact dose unknown). Twelve dogs were
receiving oral furosemide at home, without any concrete clinical evi-
dence of a previous CHF episode (defined as lack of radiographic con-
firmation and absence of clinical signs described by the owners).
The cats included in this study had a median age of 7.1 years
(range, 1.6-15.1 years), and a median weight of 4.68 kg (range,
2.45-7.20 kg). Twenty-four were male and 10 were female. The most
commonly represented breeds were European shorthair (n = 17), Brit-
ish Shorthair (n = 5), Sphynx (n = 4), and Maine Coon (n = 3). The clini-
cal data of the included cats is disclosed in Table 3. Most cats
presented with at least 2 clinical signs (23/34, 68%), with the most
common combination being tachypnea, dyspnea or both, and lethargy
(12/34, 35%). Thirty-one cats were in left-sided CHF and 3 cats were
in right-sided CHF. As described in Table 2, 11 cats were already under
treatment at the time of admission, consisting mostly of furosemide
either administered at home without concrete clinical evidence of a
TABLE 2 Treatment administered prior to admission in the included cases
Treatment at admission n % Median dose Range of dose
Dogs (n = 46) Furosemide 16 35% 3.74 mg/kg/daya 1.48-5.20
Pimobendan 16 35% 0.30 mg/kg BID 0.16-0.36
Benazepril 14 30% 0.39 mg/kg SID 0.21-0.54
Spironolactone 8 17% 2.86 mg/kg SID 1.68-3.92
Codeine 3 7% 1.89 mg/kg SID 0.76-6.90
Amoxicillin-clavulanic acid 2 4% 16.40 mg/kg BID 14.12-18.75
Predisolone 2 4% 0.60 mg/kg BID 0.4-0.71
Atenolol 2 4% 1.0 mg/kg BID 0.75-1.33
Ramipril 1 2% 0.15 mg/kg SID /
Levothroxine 1 2% 9.1 μg/kg BID /
Cats (n = 34) Furosemide 9 26% 1.98 mg/kg/daya 1.58-3.16
Pimobendan 2 6% 0.28 mg/kg BID 0.20-0.36
Benazepril 1 3% 0.74 mg/kg SID /
Clopidogrel 1 3% 18.75 mg/cat /
Aspirin 1 3% 5.71 mg/kg every 3 days /
Mirtazapine 1 3% 1.10 mg/kg every 3 days /
Methimazole 1 3% 0.5 mg/kg BID /
aMedian calculated with the known dosages only (n = 12/16 for dogs and n = 4/9 for cats).
TABLE 3 Clinical data of the cats included in the retrospective




Mitral dysplasia 6 18%
RCM 3 9%
UCM 2 6%
Tricuspid dysplasia 1 3%
Cor triatriatum sinister 1 3%
Arrhythmias
Atrial fibrillation 2 6%




Abdominal distension 4 12%
Syncope 4 12%
Coughing 3 9%
Exercise intolerance 3 9%
Cyanosis 1 3%
Type of CHF
Pulmonary edema 28 82%
Pleural effusion 18 53%
Ascites 3 9%
Abbreviations: LVH, left ventricular hypertrophy; RCM, restrictive
cardiomyopathy; UCM, unclassified cardiomyopathy; VPC, ventricular
premature complexes.
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previous CHF episode (n = 4) or administered by the referring veteri-
narian at the time of referral (n = 5; exact dose unknown). One cat had
well controlled hyperthyroidism under treatment with methimazole.
3.2 | Serum electrolyte concentrations
The results of the electrolyte panels performed upon admission are
summarized in Table 4. In the complete study sample, electrolyte
abnormalities were identified in 47/80 cases, in 52% of dogs (24/46)
and 68% of cats (23/34). Decreased electrolyte concentrations were
identified in 48% of the cases (17/46 and 21/34 in dogs and cats
respectively), and 11% showed increased electrolyte concentrations
(7/46 and 2/34, respectively). In both dogs and cats, the most com-
monly encountered electrolyte anomaly upon admission was
hypochloremia identified in 24% of all cases. The most commonly
increased electrolyte was Na, with 9% of all cases showing hyper-
natremia (5/46 and 2/34, respectively).
A similar pattern was observed in the “furosemide-naïve” sub-
group, with electrolyte abnormalities identified in 23/54 (43%) cases,
in 30% of the dogs (9/30) and 58% of the cats (14/24), and the most
commonly encountered electrolyte anomaly being hypochloremia,
present in 17% of the cases (3/30 dogs and 6/24 cats). The
furosemide-naïve dogs had significantly higher serum chloride con-
centrations on admission compared to dogs that received furosemide
prior to admission (Figure 1, P < .001). No such finding was made in
cats (P = .863). Hypochloremia was also the most commonly observed
electrolyte anomaly in the subgroup of animals in left-sided CHF
(in 9/41 dogs and 9/31 cats, 25% of the cases).
3.3 | Duration of hospitalization
Three dogs and 2 cats did not survive hospitalization. One dog and
the 2 cats succumbed to cardiopulmonary arrest refractory to resusci-
tation. The 2 other dogs were euthanized, 1 due to refractory CHF,
and the other for mixed reasons (refractory CHF and acute kidney
injury). In the subset of 43 dogs and 32 cats that survived until dis-
charge, the median duration of hospitalization was 40 hours (range,
1-146 hours) and 52 hours (range, 1-115 hours), respectively.
After correction for multiple testing, there was no significant rela-
tionship between electrolyte concentrations on admission and dura-
tion of hospitalization (corrected P-values of .29 for Na, 1 for K, .08
for Cl and 1 for corrected Cl in dogs, and 1 for all electrolytes in cats).
A similar observation was made in the left-sided CHF subgroup
(corrected P-values of .65 for Na, 1 for K, .1 for Cl and 1 for corrected
Cl in dogs, and 1 for all electrolytes in cats).
3.4 | Treatment
The details of the cardiac medications prescribed at discharge were
available for all animals who survived hospitalization (n = 43 dogs and
n = 32 cats) and are listed in Table 5. The median dose of furosemide
at discharge prescribed was 5.2 mg/kg/day (range 1.72-9.57 mg/kg/day)
for dogs and 3.53 mg/kg/day (range 1.47-7.58 mg/kg/day) in cats. Five
dogs and 2 cats were discharged on torasemide instead of furosemide at
a median dose of 0.28 mg/kg/day in dogs (range, 0.21-0.50 mg/kg/day)
and 0.23 mg/kg/day in cats (range, 0.21-0.24 mg/kg/day). As described
in the materials and methods, these animals were excluded from the sta-
tistical analyses focusing on diuretic dose.
Table 6 summarizes the correlation coefficients between each
of the electrolytes and furosemide dose at discharge. A significant
and moderate negative association was found between serum Cl
concentration at admission and total furosemide dose at discharge
in dogs (n = 38; r = 0.59; P < .001, Figure 1A). No such observa-
tion was made in cats (n = 30). No significant association was
identified with Na or K in either dogs or cats. No significant corre-
lation was observed with corrected Cl (P = .25 in dogs and P = 1
in cats).
Taking into account the significant difference in serum Cl
concentrations between dogs who received furosemide prior to
admission and dogs who never received furosemide before admission
F IGURE 1 Scatter plot demonstrating correlation between serum
chloride concentration on admission (mmol/L) and furosemide dose
(mg/kg/day) in all dogs at discharge (A) and at end-stage (B). The full
line represents the linear association between chloride on admission
(independent variable) and Y (depending on the graph, dependent
variable) found with a simple linear model
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(ie, “furosemide-naïve” dogs) (P < .001), a Spearman rank correlation
coefficient was calculated to assess the association between Cl con-
centration and diuretic doses at discharge in the subgroup of
furosemide-naïve animals, which remained significant in dogs
(r = 0.58; P = .007, Table 6, Figure 2A). Additionally, a similar signifi-
cant association between Cl concentrations and furosemide dose at
discharge was also observed in the subgroup of left-sided CHF cases
(r = 0.41; P = .004).
Diuretic dose at end-stage of disease was available for 27 dogs
and 14 cats. The median dose of furosemide at end-stage was 4.7 mg/kg/
day (range 2.02-7.28 mg/kg/day) in dogs and 3.34 mg/kg/day (range
1.61-6.60 mg/kg/day) in cats. Four dogs and 4 cats were receiving tor-
asemide instead of furosemide at end-stage, at a median dose of 0.67 mg/
kg/day in dogs (range, 0.2-1.02 mg/kg/day) and 0.35 mg/kg/day (range,
0.30-0.75 mg/kg/day) in cats and were excluded from the analyses focus-
ing on diuretic doses.
A significant and moderate negative association was found
between serum Cl concentration at admission and total furosemide
dose at end-stage in dogs (n = 23; r = 0.62; P = .005, Figure 1B), as
illustrated in Table 7. Furthermore, this association remained signifi-
cant in the subgroup of furosemide-naïve dogs (n = 16; r = 0.62;
P = .029, Table 7, Figure 2B), and in the subgroup of animals in left-
TABLE 5 Treatment prescribed at discharge in the included cases
Treatment at discharge n % Median dose Range of dose
Dogs (n = 43) Furosemide 38 88% 5.20 mg/kg/day 1.72-9.57
Torasemide 5 12% 0.28 mg/kg/day 0.21-0.50
Pimobendan 43 100% 0.28 mg/kg BID 0.19-0.36
Benazepril 36 84% 0.30 mg/kg SID 0.19-0.62
Spironolactone 31 72% 2.22 mg/kg SID 1.20-3.92
Digoxin 7 16% 0.0070 mg/kg BID 0.004-0.016
Atenolol 3 7% 1.33 mg/kg BID 0.19-1.49
L-Carnitine supplement 3 7% Unknown Unknown
Diltiazem 2 5% / 1.58-1.85 mg/kg TID
Taurine 1 2% 60.6 mg/kg BID /
Prednisolone 1 2% 0.36 mg/kg SID /
Omeprazole 1 2% 0.95 mg/kg BID /
Cats (n = 32) Furosemide 30 94% 3.53 mg/kg/day 1.47-7.58
Torasemide 2 6% 0.23 mg/kg/day 0.21-0.24
Clopidogrel 18 56% 18.75 mg/cat SID /
Benazepril 13 41% 0.29 mg/kg SID 0.21-0.74
Pimobendan 12 38% 0.26 mg/kg BID 0.19-0.36
Spironolactone 9 28% 2.17 mg/kg SID 1.67-3.57
Imidapril 7 22% 0.25 mg/kg SID /
Sotalol 3 9% 4.08 mg/kg BID 3.74-7.69
Atenolol 3 9% 1.39 mg/kg BID 1.04-1.84
Aspirin 2 6% / 3.57-5.71 mg/kg every 3 days
Methimazole 2 6% / 0.54-0.86 mg/kg SID
Amoxicillin-clavulanic acid 2 6% / 11.78-13.90 mg/kg BID
Mirtazapine 2 6% 3.75 mg/cat every 3 days /
TABLE 6 Spearman correlation coefficients between electrolytes at admission and furosemide doses at discharge
Electrolytes
All dogs (N = 38) Furosemide-naïve dogs (N = 26) All cats (N = 30) Furosemide-naïve cats (N = 20)
Furosemide dose discharge Furosemide dose discharge Furosemide dose discharge Furosemide dose discharge
Na 0.21 (P = .81) 0.24 (P = .6) 0.12 (P = 1) 0.16 (P = 1)
K 0.31 (P = .25) 0.37 (P = .18) 0.25 (P = .7) 0.46 (P = .17)
Cl 0.59 (P < .001) 0.58 (P = .007) 0.18 (P = 1) 0.16 (P = 1)
Notes: The P value presented are corrected for multiple testing with Bonferroni correction, and significant results obtained are bolded.
Abbreviations: Cl, chloride; K, potassium; Na, sodium.
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sided CHF (r = 0.51; P = .017). Comparably to discharge dosages,
no significant association was identified with Cl concentrations in
cats, and neither with Na or K concentrations in both species. No sig-
nificant correlation was identified with corrected Cl concentrations
(P = .11 in dogs and P = 1 in cats).
3.5 | Survival analysis
Follow-up data was available for all dogs and 32 cats. Four dogs and
1 cat were excluded from the survival analysis due to euthanasia for
noncardiac or mixed reasons. One cat was excluded based on a high
suspicion of reversible myocarditis with resolution of the echocardio-
graphic anomalies. The median survival time observed after first CHF
episode was 125 days in dogs (n = 42; range, 3-1217 days) and
141 days in cats (n = 30; range, 1-1804 days). As illustrated by
Table 8, no effect of electrolyte concentrations on time to cardiac
mortality was identified, nor was there a correlation with corrected Cl
concentrations (P = 1 in both dogs and cats). A similar observation
was made in the subgroup of left-sided CHF cases (P = 1 in both dogs
and cats for all electrolytes).
4 | DISCUSSION
In this study, the admission serum electrolyte concentrations and their
relationship with duration of hospitalization, diuretic doses both at
discharge and at disease end-stage, and survival time in 80 dogs and
cats presented with acute CHF were documented. Electrolyte abnor-
malities are not uncommon in dogs and cats presented for a first epi-
sode of acute CHF, with hypochloremia being the most frequently
encountered abnormality, independent of the prior administration of
loop diuretics. To our knowledge, this is the first study documenting
electrolyte abnormalities on admission in dogs and cats with a first
episode of acute CHF. Our findings are consistent with a previous ret-
rospective study including 145 dogs and cats with acute CHF, show-
ing hypochloremia in 31% of the cases, though in that report not all
animals included were in their first episode of CHF and some were
included several times.20 The observed prevalence in dogs and cats is
higher than in people, where hypochloremia is observed in 7.4% to
13% of the cases.8,14,21
A significant and moderate negative correlation was identified
between serum Cl concentrations and furosemide doses both at dis-
charge and at end-stage disease in dogs. This association represents a
clinically important finding of the present study. This finding advo-
cates for assessment of serum Cl concentration in dogs with acute
CHF, and suggests that, even during a first episode of CHF, this vari-
able might help identify dogs who could require larger doses of
diuretics, illustrating the potential of Cl as a marker for disease sever-
ity and response to diuretic therapy. Several large clinical studies have
established this relationship in people, and have advanced that
hypochloremia could serve as a marker of impaired diuretic response
in HF patients.7,13,14,21 Moreover, high diuretic doses have been sig-
nificantly associated with poor outcome in people,22 implying that
F IGURE 2 Scatter plot demonstrating correlation between serum
chloride concentration on admission (mmol/L) and furosemide dose
(mg/kg/day) in furosemide-naïve dogs at discharge (A) and at end-
stage (B). The full line represents the linear association between
chloride on admission (independent variable) and Y (depending on the
graph, dependent variable) found with a simple linear model
TABLE 7 Spearman correlation coefficients between electrolytes at admission and furosemide doses at end-stage
Electrolytes
All dogs (N = 23) Furosemide-naïve dogs (N = 16) All cats (N = 10) Furosemide-naïve cats (N = 8)
Furosemide dose end-stage Furosemide dose end-stage Furosemide dose end-stage Furosemide dose end-stage
Na 0.04 (P = 1) 0.03 (P = 1) 0.29 (P = 1) 0.02 (P = 1)
K 0.10 (P = 1) 0.09 (P = 1) 0.35 (P = 1) 0.45 (P = 1)
Cl 0.62 (P = .005) 0.62 (P = .029) 0.18 (P = 1) 0.19 (P = 1)
Notes: The P value presented are corrected for multiple testing with Bonferroni correction, and significant results are bolded.
Abbreviations: Cl, chloride; K, potassium; Na, sodium.
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hypochloremia could carry prognostic evidence by itself in small
animals.
Diuretic resistance has no single-accepted definition, but is most
frequently known as “failure to decongest despite adequate doses of
diuretics.”23 It is well established that many human patients with
acute CHF are or become resistant to loop diuretics.24 From a patho-
physiological perspective, the relationship between serum Cl and
diuretic resistance is complex, and incompletely understood. In
people, hypochloremia is suspected to be secondary to excess of
angiotensin II, AVS-mediated dilution, loop-diuretic use, and altered
acid-base homeostasis, all of which are typically present in CHF.12,25
Furthermore, hypochloremia might by itself drive central mechanisms
contributing to diuretic resistance. Firstly, Cl seems to bind directly to
the catalytic site of a family of serine-threonine kinases, regulating
their ability to influence important Na regulatory pathways, the RAAS,
but also the transporters through which loop and thiazide diuretics
mediate their effect.26-29 Additionally, Cl plays a major role in acid-
base homeostasis, and its depletion takes part in the process driving
metabolic alkalosis states.11,30 Finally, the identification of genetic
variants with a mutation in the code for a renal Cl channel associated
with an increased risk of advanced HF provides further belief that Cl
might occupy a more central role in HF than previously suspected.31
Although diuretic resistance is suspected to occur in small animals
with CHF as well, it is poorly defined and reports are scarce. Recently,
a study compared electrolyte concentrations, indices of diuretic effi-
cacy and RAAS activation markers in dogs with various stages of heart
disease.15 In that study, a few dogs in stage D HF with evidence of
reduced diuretic efficacy had a more pronounced hypochloremia than
the ones with adequate diuretic response. This supports the role of Cl
as a marker or driver of diuretic resistance in dogs. However, chronic
HF dogs were included, contrasting notably with our sample of dogs
and cats in their first presentation of acute CHF, which were selected
in accordance with several cohort-based studies in people.7,8,13 The
mutual findings of both studies might refer to distinct aspects of
diuretic resistance. While it was demonstrated that serum Cl concen-
trations strongly differentiates between stages C and D in dogs with
HF,15 the results of the present study suggest that Cl concentrations
could pinpoint the presence of an intrinsic difference in response to
loop-diuretics at the time of the first episode of CHF. The pathophysi-
ology behind this individual responsiveness is not known, but pharma-
cokinetic issues and additional compensatory Na reabsorption have
been described in diuretic resistant people.32 Our study focused solely
on diuretic doses administered as a marker of response to diuretic
therapy, and further studies in dogs and cats with acute CHF are
required to assess the correlation in dogs and cats with acute CHF
between serum Cl concentrations and markers of diuretic resistance
validated in humans, such as diuretic efficacy (defined as urine output
relative to the dose of furosemide administered), Na excretion frac-
tion, urine Na-to-K ratio, and urinary Na concentration.33
As mentioned above, considering that loop diuretic therapy is
1 of the main contributors of electrolyte depletion in CHF cases, and
the retrospective nature of our study, the order of causality of the
correlation between hypochloremia and administered furosemide
doses remains unclear. It could be argued that hypochloremia is
mainly a consequence of the administration of high doses of loop
diuretics in our cases. However, our study identified a similar signifi-
cant correlation between Cl concentrations and furosemide doses in
the subgroup of furosemide-naïve dogs. This suggests that, indepen-
dently of previous loop-diuretic administration, hypochloremia identi-
fied upon admission is significantly associated with the administration
of higher diuretic doses, highlighting the potential of Cl as a clinically
relevant marker in dogs with acute CHF.
No such correlation was identified with Na concentrations, which
is consistent with the most recent literature available in people with
CHF, where hypochloremia in the absence of hyponatremia remained
prognostically significant.7,9 Additionally, no significant findings were
observed for corrected Cl concentrations, which per definition take
Na concentrations into account. Whether this lack of significant P-
values is the result of our small sample size, the retrospective nature
of our study, or the absence of direct effect from the Na concentra-
tion itself is not known at this time. Interestingly, no correlation with
any electrolyte was identified in cats. This could be secondary to our
relatively small sample group, but could also suggest a variability in
the underlying mechanism driving diuretic response in the feline
species.
No significant association between electrolyte concentrations
and duration of hospitalization was identified in our study. However,
the P-value for Cl in dogs approached significance. Potentially, a larger
and statistically more powerful study could disclose significantly lon-
ger hospitalization durations for hypochloremic dogs, as it has been
described in people.7
No significant hazard ratios were obtained after Cox proportional
hazard regression for survival time. The absence of significant impact
of hyponatremia is consistent with the most recent reports in the
TABLE 8 Cox proportional hazards regression model to assess the potential effect of electrolyte concentration on time to cardiac mortality
Dogs (N = 42) Cats (N = 30)
Electrolytes Hazard ratio 95% CI Corrected P-value Hazard ratio 95% CI Corrected P-value
Na 0.976 0.923-1.033 1 1.027 0.935-1.129 1
K 0.602 0.322-1.125 .45 0.983 0.479-2.017 1
Cl 0.958 0.903-1.017 .62 1.022 0.955-1.094 1
Notes: The P value presented are corrected for multiple testing with Bonferroni correction.
Abbreviations: Cl, chloride; K, potassium; Na, sodium.
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human literature.7,8,14 Nonetheless, this finding contrasts with a previ-
ous retrospective study performed on 59 dogs with CHF disclosing
significantly lower plasma Na concentrations in dogs failing to survive
until discharge.6 One explanation for this disparity resides in the num-
ber of dogs surviving until discharge (56% against 93% in our study).
Follow-up after discharge was also not recorded.
Likewise, serum K concentration did not impact survival in our
study. This result contrasts with another retrospective study per-
formed on 145 dogs showing greater survival to discharge for hypoka-
lemic cases.20 However, contrary to our study, the authors focused on
electrolyte abnormalities during hospitalization as opposed to admis-
sion parameters, and did not include any follow-up information.
Finally, no effect of Cl concentration on survival was noted in our
study, in contrast to the body of literature available in people.7-14,21,25
However, differences in study design could account for this discrep-
ancy. Many of these clinical studies were aiming at comparing the sur-
vival between classes of Cl concentrations.7,13,14,21 However, our
sample size was small compared to the large human clinical studies,
which made it difficult to compare survival times between Cl classes,
and it is possible that such an influence was not noticeable in our sam-
ple due to its size.
Our study has other limitations, mostly inherent to its retrospec-
tive design. Medical treatments administered prior to admission were
not standardized, and the effect of the use of any other medication
besides loop diuretics was not analyzed. Although belonging to the
diuretics category, the effect of prior administration of spironolactone
was not examined in our study, which could theoretically have altered
the results. However, its mechanism of action and the previous
reports available in the human literature disclosing a lack of associa-
tion between spironolactone use and lower serum Cl concentrations21
might support the validity of our results. Similarly, the animals' diet
was not taken into account, which might have led to differences in
dietary amounts of electrolytes and influenced our findings. Prospec-
tive studies with standardized treatment protocols are needed to
completely rule out the potential influence of other medications
and diet.
To maximize the number of cases included in the statistical ana-
lyses, our main study group comprised of both left-sided and right-
sided CHF cases. The differences in pathophysiology between these
2 subgroups could lead to substantial variations in electrolyte concen-
trations, diuretic regimen, and prognosis. We tried to answer to this
bias by repeating the analyses on the left-sided CHF subgroup, show-
ing similar results to those obtained in the complete study sample.
However, the small number of right-sided CHF cases included made
meaningful statistical analysis in this subgroup impossible. Further
studies focusing on animals with ascites, pleural effusion or both are
needed to confirm our findings in right-sided CHF cases.
As per definition in a retrospective design, treatment adminis-
tered during hospitalization was also not standardized, and cases were
supervised by different cardiologists. However, clinicians at our insti-
tution shared a relatively similar therapeutic management approach,
based on clinical parameters such as respiratory rate and effort, limit-
ing the subjectivity of the doses administered. The latter were
selected on a case-by-case basis, using the published recommenda-
tions available at the time of inclusion,34,35 with an average starting
dose of furosemide of 2 mg/kg, and adapting the subsequent furose-
mide administrations according to evolution of the breathing status
and frequency, and appetite. In case furosemide doses necessary to
achieve clinical stabilization were deemed too extreme, the animal
was switched to torasemide at the time of transfer from injectable to
oral medications. The patient was discharged when his respiratory
condition was deemed stable enough with oral medication for at least
12 hours. Additionally, as recommended in the literature,34,35 the
need for K-supplementation was assessed based on the results of
the serum electrolytes concentrations. The serum Cl concentration by
itself was not taken into account in the diuretic dose decision-making
process.
The gold standard for confirmation of left-sided CHF, thoracic
radiography, was not performed in all cases. When radiography was
unavailable, we attempted to ensure accurate inclusion of dogs and
cats in CHF by relying on the combination of the history, clinical signs,
physical examination findings, and point-of-care ultrasound assess-
ments performed by experienced cardiologists, as previously
described.16,17 The reference intervals provided by the manufacturer
of our auto-analyzer for the electrolytes concentrations were not vali-
dated in a local sample. Finally, this study has a relatively small sample
size, and was performed in a single referral center, and the results
might thus not apply to all CHF cases.
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